Abstract
In recent years, we have witnessed a revolution in the treatment of coronary artery disease. The development and improvement of drug eluting stents (DES) have lowered the incidence of restenosis to one-digit figures. In the search for a superior efficacy, animal models have played a key role. The classical swine model of coronary stenting remains the preferred model to measure restenosis, although the rabbit iliac artery stenting has become an accepted alternative. After widespread clinical use of DES, an unforeseen complication arose: late stent thrombosis. In a back-to-bench step, some data from animal models helped to explain the phenomenon. A delayed and incomplete vascular healing was detected. Toxic and hypersensitivity reactions to polymers and/or drugs seem to be the underlying causes. So, translational research focused on the safety aspect of these devices: development of better drug carriers as absorbable polymers or fully bioresorbable scaffolds, selection of different drugs and assessment of the re-endothelialization process. We review and evaluate the efficacy and safety of coronary stents in different animal models. Further improvements in this field such as, the selection of better animal models (e.g. hyperlipidemic, diabetic, atherosclerotic) that closely mimic the clinical setting and longer follow-up periods to detect late complications are also discussed.
Keywords: Animal model, drug eluting stent, endothelium, inflammation, percutaneous coronary intervention, safety, stent thrombosis vascular healing
Current Vascular Pharmacology
Title:Preclinical Evaluation of Coronary Stents: Focus on Safety Issues
Volume: 11 Issue: 1
Author(s): Armando Perez de Prado, Claudia Perez-Martinez, Carlos Cuellas, Jose M. Gonzalo-Orden, Alejandro Diego, Marta Regueiro, Beatriz Martinez-Fernandez, Jose R. Altonaga, J. Francisco G. Marin and Felipe Fernandez-Vazquez
Affiliation:
Keywords: Animal model, drug eluting stent, endothelium, inflammation, percutaneous coronary intervention, safety, stent thrombosis vascular healing
Abstract: In recent years, we have witnessed a revolution in the treatment of coronary artery disease. The development and improvement of drug eluting stents (DES) have lowered the incidence of restenosis to one-digit figures. In the search for a superior efficacy, animal models have played a key role. The classical swine model of coronary stenting remains the preferred model to measure restenosis, although the rabbit iliac artery stenting has become an accepted alternative. After widespread clinical use of DES, an unforeseen complication arose: late stent thrombosis. In a back-to-bench step, some data from animal models helped to explain the phenomenon. A delayed and incomplete vascular healing was detected. Toxic and hypersensitivity reactions to polymers and/or drugs seem to be the underlying causes. So, translational research focused on the safety aspect of these devices: development of better drug carriers as absorbable polymers or fully bioresorbable scaffolds, selection of different drugs and assessment of the re-endothelialization process. We review and evaluate the efficacy and safety of coronary stents in different animal models. Further improvements in this field such as, the selection of better animal models (e.g. hyperlipidemic, diabetic, atherosclerotic) that closely mimic the clinical setting and longer follow-up periods to detect late complications are also discussed.
Export Options
About this article
Cite this article as:
Perez de Prado Armando, Perez-Martinez Claudia, Cuellas Carlos, M. Gonzalo-Orden Jose, Diego Alejandro, Regueiro Marta, Martinez-Fernandez Beatriz, R. Altonaga Jose, Francisco G. Marin J. and Fernandez-Vazquez Felipe, Preclinical Evaluation of Coronary Stents: Focus on Safety Issues, Current Vascular Pharmacology 2013; 11 (1) . https://dx.doi.org/10.2174/1570161111309010074
DOI https://dx.doi.org/10.2174/1570161111309010074 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fibrates and Statins in the Treatment of Diabetic Retinopathy
Current Pharmaceutical Biotechnology Withdrawal Notice: Reconnoitering the Role of Endothelin in Obesity
Current Pharmaceutical Design T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets Pioglitazone Therapy and Fractures: Systematic Review and Meta- Analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets Improved Insulin Resistance through Cajanus cajan extract in Gestational Diabetes Mellitus of Wistar Rat
Current Women`s Health Reviews Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Transcatheter Aortic Valve Implantation Infective Endocarditis: Current Data and Implications on Prophylaxis and Management
Current Pharmaceutical Design Imaging in Diabetic Retinopathy: A Review of Current and Future Techniques
Current Diabetes Reviews Nongenomic Thyroxine Regulation of Voltage-gated Sodium Current During Embryonic Development
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Central Pre-proglucagon Derived Peptides: Opportunities for Treatment of Obesity
Current Pharmaceutical Design Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors
Current Pharmaceutical Design Adrenomedullin Function in Vascular Endothelial Cells: Insights from Genetic Mouse Models
Current Hypertension Reviews Diet and Contaminants: Driving the Rise to Obesity Epidemics?
Current Medicinal Chemistry Editorial (Thematic Issue: Mitochondria in Human Diseases and Animal Evolution)
Current Molecular Medicine Genetic Association Studies in Diabetic Nephropathy
Current Diabetes Reviews Influence of Lifestyle Measures on Hypertriglyceridaemia
Current Drug Targets Pulmonary Pathology Among Patients with Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-analysis
Current Diabetes Reviews Autoimmune Diabetes Mellitus: The Importance of Autoantibodies for Disease Prediction and Diagnostic Support
Current Immunology Reviews (Discontinued) Adherence to Mediterranean Diet Offers an Additive Protection Over the Use of Statin Therapy: Results from the ATTICA Study (2002-2012)
Current Vascular Pharmacology